Hypertension: RAS blockade, hyperkalemia and AKI-look and you will find

Robert D. Toto

doi:10.1038/nrneph.2012.62

Hypertension: RAS blockade, hyperkalemia and AKI-look and you will find

Robert D. Toto

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

Original language	English (US)
Pages (from-to)	257-258
Number of pages	2
Journal	Nature Reviews Nephrology
Volume	8
Issue number	5
DOIs	https://doi.org/10.1038/nrneph.2012.62
State	Published - May 1 2012

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/nrneph.2012.62

Cite this

@article{25f7b3280a8c438f94154a4f062ad40f,

title = "Hypertension: RAS blockade, hyperkalemia and AKI-look and you will find",

abstract = "Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.",

author = "Toto, {Robert D.}",

year = "2012",

month = may,

day = "1",

doi = "10.1038/nrneph.2012.62",

language = "English (US)",

volume = "8",

pages = "257--258",

journal = "Nature Clinical Practice Nephrology",

issn = "1759-507X",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Hypertension

T2 - RAS blockade, hyperkalemia and AKI-look and you will find

AU - Toto, Robert D.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

AB - Aliskiren combined with other inhibitors of the renin-angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

UR - http://www.scopus.com/inward/record.url?scp=84860300791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860300791&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2012.62

DO - 10.1038/nrneph.2012.62

M3 - Article

C2 - 22473512

AN - SCOPUS:84860300791

SN - 1759-507X

VL - 8

SP - 257

EP - 258

JO - Nature Clinical Practice Nephrology

JF - Nature Clinical Practice Nephrology

IS - 5

ER -

Hypertension: RAS blockade, hyperkalemia and AKI-look and you will find

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this